Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;2(4):e1170.
doi: 10.1002/cnr2.1170. Epub 2019 Mar 24.

Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute

Ka Chai Eric Lee  1 , Wing Ho Mui  1 , Wai Chan  1 , Chi Sing Frank Wong  1 , Sau Kwan Peggy Chu  2
Affiliations

Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute

Ka Chai Eric Lee et al. Cancer Rep (Hoboken). 2019 Aug.

Abstract

Background: Meta-analysis had shown a significant 5% absolute survival benefit in favour of neoadjuvant chemotherapy (NAC) with cisplatin-based chemotherapy before radical cystectomy (RC) and pelvic lymphadenectomy (PLND) for patients with muscle invasive bladder cancer (MIBC). Those who had pathological complete response (pCR) to NAC could have long-term progression-free survival (PFS) and overall survival (OS).

Aim: To identify the treatment and patient factors which could predict a pCR to NAC and the associated PFS and OS in a single institute.

Methods and results: We retrospectively reviewed the records of patients who had received NAC with gemcitabine and cisplatin (GC) in our centre from January 2004 to December 2017. The patients' age, tumour stage, baseline estimated glomerular filtration rate (eGFR), chemotherapy chart, and pathological information were recorded. There were 25 men and five women who had received NAC followed by RC. pCR was noted in the surgical specimen of 11 (37%) patients. The mean dose of gemcitabine was significantly higher in the pCR group than the non-pCR group (9850 vs 7852 mg, P = 0.039) as was the dose-intensity of cisplatin (87.4% vs 71.3%, P = 0.044). After a median follow-up of 38 months (range 4.3-154), seven patients had disease progression. The estimated 3-year PFS is 74.9% (95% confidence interval [CI], 66.7%-83.3%). None of the patients who achieved pCR relapsed, while six out of seven patients who had pN1 disease developed distant metastasis (DM). Only two patients died of DM while two other patients died of unrelated causes. The estimated 3-year OS is 88.9% (95% CI 82.8%-95%).

Conclusions: We have demonstrated that the dose intensity of GC is a major determinant of pCR, which predicts longer RFS and OS. Further research in gene expression profiling of MIBC to help selecting patient for NAC is needed.

Keywords: bladder; chemotherapy; urologic Cancer.

PubMed Disclaimer

Conflict of interest statement

All authors have no conflicts of interest to disclose. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

Figures

Figure 1
Figure 1
Progression free survival
Figure 2
Figure 2
Overall survival
See this image and copyright information in PMC

References

    1. Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD‐EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma–neoadjuvant and adjuvant settings. Eur Urol. 2013;63(1):58‐66. - PubMed
    1. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed in Oct 2018
    1. Meeks JJ, Bellmunt J, Bochner BH, et al. A systemic review of neoadjuvant and adjuvant chemotherapy for muscle‐invasive bladder cancer. Eur Urol. 2012;62(3):523‐533. - PubMed
    1. Culp SH, Dickstein RJ, Barton Grossman H, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014;191(1):40‐47. - PMC - PubMed
    1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder Cancer. NEJM. 2003;349(9):859‐866. - PubMed

MeSH terms